Anakinra to Prevent Adverse Post-infarction Remodeling (2)
Completed · Phase 2 · Has a placebo group
Conditions studied: Acute Myocardial Infarction, Heart Failure
In brief
Acute myocardial infarction (AMI) remains a major cause of morbidity and mortality. Many patients die early during the course, and those who survive are at risk for dying late from adverse cardiac remodeling and heart failure. The initial ischemic damage to the myocardium initiates an intense inflammatory response in promoting further cardiac dysfunction and heart failure. The investigators propose that an antiinflammatory strategy based on blockade of Interleukin-1 will quench the inflammatory response and lead to a more favorable cardiac remodeling process.
Key facts
- Study ID
- NCT01175018
- Run by
- Virginia Commonwealth University
- People needed
- 30
- Starts
- 2010-07-01
- Expected to finish
- 2012-12-01
- Last updated by the study team
- 2016-05-23
Who can join
Age: 18 and older, up to 110. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with STEMI will be asked to enroll according to the following inclusion criteria:
- age > 18 years,
- acute (<12 h) onset of chest pain associated with ST segment elevation (>2 mm) in 2 or more anatomically contiguous leads at ECG,
- and successful primary percutaneous coronary intervention.
You may not qualify if…
- inability to give informed consent,
- late presentation (>12 h),
- unsuccessful revascularization procedure,
- hemodynamic instability including hypotension,
- prior Q-wave AMI,
- end-stage congestive heart failure (American Heart Association [AHA]/American College of Cardiology [ACC] class C-D, New York Heart Association IV), severe left ventricular dysfunction (EF<20%),
- severe valvular heart disease,
- pregnancy, dye allergy or contraindications to cardiac angiography and/or magnetic resonance imaging, coagulopathy (INR>1.5 or platelet count<50000/mm3),
- recent (<14 days) use of anti-inflammatory drugs (not including NSAIDs),
- chronic inflammatory disease (including but not limited to rheumatoid arthritis, systemic lupus erythematosus), and malignancy or any comorbidity limiting survival or conditions predicting inability to complete the study.
Where it is running
- Virginia Commonwealth University — Richmond, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.